The Trauma INtramuscular Tranexamic Acid Clinical Trial

• Status: Completed
• Trial end date: 2020-02-12
• Target enrollment: 0
• Participant gender: All

Summary

Intramuscular injection of tranexamic acid (TXA) would increase its use in situations where administration of intravenous drugs is difficult. The investigators aim to assess the population pharmacokinetics of intramuscular TXA in trauma patients.

Primary endpoint: Serum TXA concentrations over time. Secondary endpoints: Local reactions at injection sites and adverse events

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: London School of Hygiene and Tropical Medicine
• Collaborators: Barts & The London NHS Trust; JP Moulton Charitable Foundation; St George's University Hospitals NHS Foundation Trust; University of Versailles
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Adult (appear to be at least 16 years old) trauma patients who have received 1 gram of intravenous TXA for the management of haemorrhage in whom a second dose is clinically indicated are eligible.

Exclusion Criteria:

• none